


1634



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mealey and Bentjen

Art Unit: 1634

Application No. 10/044,671

Filed: January 10, 2002

For: MDR1 VARIANTS AND METHODS FOR  
THEIR USE

Examiner: Sally A. Sakelaris

Date: June 10, 2003

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on June 10, 2003, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Tanya M. Harding, Ph.D.  
Attorney for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Enclosed for filing in the application referenced above are the following:

- ☒ Supplemental Information Disclosure Statement
  - ☒ Form 1449 and copies of the 7 references cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446  
cc: Docketing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of: Mealey and Bentjen

Art Unit: 1634

Application No. 10/044,671

Filed: January 10, 2002

For: MDR1 VARIANTS AND METHODS FOR THEIR USE

Examiner: Sally A. Sakelaris

Date: June 10, 2003

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on June 10, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Tanya M. Harding, Ph.D.  
Attorney for Applicant

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file the IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please see the attached Transmittal Letter for Deposit Account authority.

The filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4630-61733
Application Number	10/044,671
Filing Date	January 10, 2002
First Named Inventor	Mealey
Art Unit	1634
Examiner Name	Sally A. Sakelaris

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Jun <i>et al.</i> , "Insertion of a retroviral solo long terminal repeat in mdr-3 locus disrupts mRNA splicing in mice," <i>Mammal. Gen.</i> 11(10):843-848, October 2000
		Mealey <i>et al.</i> , "Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the northwestern United States," <i>Am. J. Vet. Res.</i> 63(4):479-481, April 2002
		Mealey <i>et al.</i> , "Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene," <i>Pharmacogen.</i> 11(8):727-733, November 2001
		Pippert <i>et al.</i> , "The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene," <i>J. Biochem. Mol. Toxicol.</i> 15(2):83-89, 2001
		Ruetz <i>et al.</i> , "Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells," <i>Proc. Natl. Acad. Sci. USA</i> 90(24):11588-11592, 1993
		Schinkel <i>et al.</i> , "Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs," <i>Cell</i> 77(4):491-502, 1994
		Schinkel <i>et al.</i> , "N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein," <i>J. Biol. Chem.</i> 268(10):7474-7481, 1993

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.